Notes / Company

Eris Lifesciences Ltd.

ERIS BSE 540596 ISIN INE406M01024 Pharmaceuticals

Fundamentals

Market cap: ₹20,217 cr
P/E: 32.63×
ROE: 12.33%
Debt / equity: 0.85
Div yield: 0.49%
52-week range: 1200.00 — 1885.00

Research on Tijori Finance

Company snapshot

Eris Lifesciences Ltd.

Pharmaceuticals

₹20,306 cr

P/E 32.78×

Latest quarter · Mar 2026

Sales₹757 cr

Net profit₹280 cr

Op. margin+36.2%

EPS₹20.33

Strength & growth

Debt / equity0.85×

Current ratio0.89×

Sales CAGR+17.2%

EPS CAGR+9.6%

The timeline — 1 note on Eris Lifesciences Ltd.

June 2026

23 Jun 26 · 4:19 PM IST Brief

Brief · Large cap

Eris targets 18-20% international growth in FY27 despite EU site snag

A corporate presentation reveals fresh FY27 guidance for the international business and confirms an EU inspection that delayed commercialisation of its EU-CDMO pipeline but left existing operations intact.

Verify on exchange BSE filings for ERIS NSE filings for ERIS Tijori Finance company page